Rakovina Therapeutics Inc (TSX-V:RKV) will present preliminary results of its AI-driven drug development program at the Neuro-Oncology Annual Meeting in Houston on November 22, 2024. The virtual poster, titled “Utilizing Artificial Intelligence for the Discovery of Novel PARP1-Selective Inhibitors for Use Against Brain Tumors,” highlights the use of AI to design therapies targeting PARP1, a key protein in DNA repair. This innovative approach aims to create more effective treatments for aggressive brain cancers, such as glioblastomas, while sparing healthy cells.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com